Regeneron Faces Class Action Lawsuit Following Failed Melanoma Trial

The litigation targets Regeneron’s conduct between August 1, 2025, and May 15, 2026, a period during which management repeatedly touted the combination therapy as a potential blockbuster. According to the complaint, the company failed to disclose that the trial’s preliminary statistical assumptions were flawed and that the treatment arm showed no meaningful differentiation from standard care. While management attributed slowing event rates to the drug’s high efficacy, the lawsuit claims these delays masked the reality that the trial was unlikely to reach its primary endpoint of progression-free survival.

Regeneron’s narrative began to unravel in April 2026, when the company announced a sudden alteration to trial protocols. By May 12, the company admitted these changes had been initiated months earlier due to low event rates, a detail previously withheld from shareholders. The final collapse occurred on May 15, 2026, when Regeneron confirmed the study failed to achieve statistical significance. Lead attorney Reed Kathrein stated the firm is investigating whether these protocol shifts were used to intentionally obscure the lack of clinical benefit. Investors who suffered losses during the specified class period are now being urged to join the litigation before the September 14, 2026, deadline.